FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas

Phase 2

Terminated

Conditions: Pancreatic Cancer
Islet Cell Carcinoma
Gastro-enteropancreatic Neuroendocrine Tumor
Neuroendocrine Carcinomas of Pancreas

Interventions: Drug: FOLFIRINOX
Drug: Granulocyte colony-stimulating factor (G-CSF)

Brief Summary: The purpose of this study is evaluate the efficacy and safety of FOLFIRINOX in patients with gastroenteropancreatic high-grade neuroendocrine carcinomas.

This is a prospective Phase II open-label trial, stratifying gastroenteropancreatic high grade neuroendocrine carcinomas participants equally into two cohorts (first-line versus beyond first-line).

Recruitment & Eligibility

Inclusion Criteria

Histologically or cytologically confirmed neuroendocrine carcinoma of the gastrointestinal (GI) tract. Potential participants with unknown origin for the neuroendocrine carcinoma in which a gastroenteropancreatic origin is suspected (per pathologist or investigator discretion) will be eligible for the study.
Tumors must have a Ki-67 index greater than 20% and/or >20 mitotic figures/10 high-power fields.
Must have metastatic disease.
Must measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
Any line of treatment (first line versus beyond first line).
Age >18 years.
Life expectancy of greater than 12 weeks.
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.
Must have adequate organ and marrow function.
Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria

Have had chemotherapy or radiotherapy within 3 weeks prior to entering the study.
Receiving any other investigational agents.
Untreated brain or meningeal metastases.
Prior treatment with 5-fluorouracil (5-FU), irinotecan or oxaliplatin.
Pre-treatment peripheral neuropathy greater than grade 1 per the CTCAE, version 4.0.
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
A secondary primary cancer (excluding baso/squamous cell carcinoma of skin) within 1 year.
Active viral hepatitis or autoimmune hepatitis. The work-up to confirm active hepatitis or autoimmune hepatitis will only be done if clinical suspicion based on investigator discretion.
Potential participants with childbearing potential who are not willing to use adequate contraception precautions during the study and for 3 months after stopping study chemotherapy.

Arm && Interventions

Group	Intervention	Description
FOLFIRINOX Treatment	Granulocyte colony-stimulating factor (G-CSF)	Participants will receive modified FOLFIRINOX which consists of 85 mg/m\^2 of oxaliplatin, 400 mg/m\^2 of leucovorin over the first 2 hours, 165 mg/m\^2 of irinotecan in a 90-minute infusion on day 1, followed by a continuous, 46-hour infusion of 5-FU at a dosage of 2,400 mg/m\^2. A cycle will be repeated every 14 days. Granulocyte colony-stimulating factor (G-CSF) prophylaxis will be allowed after each cycle. Participants will undergo re-staging studies every 8 weeks. Participants will receive up to 12 cycles during the study. Additional cycles will be determined per investigators' discretion.
FOLFIRINOX Treatment	FOLFIRINOX	Participants will receive modified FOLFIRINOX which consists of 85 mg/m\^2 of oxaliplatin, 400 mg/m\^2 of leucovorin over the first 2 hours, 165 mg/m\^2 of irinotecan in a 90-minute infusion on day 1, followed by a continuous, 46-hour infusion of 5-FU at a dosage of 2,400 mg/m\^2. A cycle will be repeated every 14 days. Granulocyte colony-stimulating factor (G-CSF) prophylaxis will be allowed after each cycle. Participants will undergo re-staging studies every 8 weeks. Participants will receive up to 12 cycles during the study. Additional cycles will be determined per investigators' discretion.

Primary Outcome Measures

Name	Time	Method
Objective Radiographic Response Rate (ORR)	Up to 36 months	The primary efficacy endpoint is objective response rate as determined by radiology review, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Complete Response (CR): complete disappearance of all target lesions. Partial Response (PR): at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum longest diameter. Progressive disease (PD): at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this may include the baseline sum). Stable Disease (SD): neither sufficient decrease to qualify for partial response nor sufficient increase to qualify for progressive disease.

Secondary Outcome Measures

Name	Time	Method
Progression Free Survival (PFS)	Up to 36 months	PFS: from initiation date of therapy to disease progression or death. Progressive disease (PD): at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this may include the baseline sum).